<p><em>PureTech 将继续在伦敦证券交易所保持其主要上市</em></p>
<p><em>预计简化上市结构将提升运营效率，并将资源集中于推进公司的投资组合</em></p>
<p>波士顿 --（商业资讯）--PureTech Health plc（纳斯达克：PRTC，伦敦证券交易所：PRTC）（&#34;PureTech&#34;或&#34;公司&#34;），一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司，今天宣布已通知纳斯达克证券市场有限责任公司（“纳斯达克”）其自愿退市美国存托股票（“ADSs”）的意图，每个 ADS 代表有权接收公司十（10）股普通股。在退市生效后，PureTech 的普通股将继续在伦敦证券交易所（“LSE”）上市，该交易所将继续作为公司的主要交易场所。</p>
<p>经过对公司上市结构和股东交易模式的审查，董事会决定维持双重上市已不再必要。PureTech 股票的绝大多数交易量、流动性和价格发现发生在伦敦证券交易所，而公司当前投资者基础的主要部分以及公司的治理框架均集中在英国。</p>
<p>这一决定反映了 PureTech 对严格资本配置、专注执行和长期股东价值创造的持续承诺。维持双重上市的成本以及监管和行政要求是相当大的，集中交易于伦敦证券交易所将简化治理、精简开支，并使公司的结构与其运营和战略优先事项保持一致。</p>
<p>在退市后，直到 PureTech 考虑终止其美国存托凭证（“ADR”）计划为止，PureTech 预计其 ADS 将在场外市场通过赞助的一级 ADR 计划进行报价和交易。此时，ADS 持有者无需采取任何行动。</p>
<p>PureTech 首席执行官 Robert Lyne 评论道：</p>
<p>“我们已确定，将我们的上市集中在伦敦证券交易所是支持我们的股东和执行我们战略的最有效方式。这个决定反映了我们股票的有意义交易量和流动性始终发生的地方，同时保持对英国和全球投资社区的访问。通过简化我们的上市结构，我们正在精简开支、保护资本，并确保我们的资源集中于推进我们差异化的投资组合并创造长期价值。”</p>
<p>PureTech 预计将在 2026 年 5 月 11 日左右向美国证券交易委员会（“SEC”）提交一份 25 号表格，涉及其 ADS 的退市。退市预计将在十天后生效，PureTech 的 ADS 在纳斯达克的最后交易日预计在 2026 年 5 月 20 日左右。</p>
<p>在退市后，PureTech 打算向 SEC 提交一份 15F 表格，以注销其证券并终止其根据 1934 年证券交易法（“交易法”）的报告义务。提交该表格后，公司的报告义务将立即暂停。如果 SEC 没有异议，公司的注册和报告义务的终止预计将在提交后不超过 90 天内生效。</p>
<p><strong>关于 PureTech Health</strong></p>
<p>PureTech Health 是一家中心辐射式生物治疗公司，致力于将科学变为现实并将创新转化为价值。我们通过一种经过验证的、资本高效的研发模式来实现这一目标，专注于具有验证药理学和未开发潜力的机会，以满足重要的患者需求。这一战略已经产生了数十个治疗候选药物，其中三个已获得美国 FDA 批准。通过识别、塑造和降低这些高信念资产的风险，并通过外部资本支持的专门结构进行规模化，我们加速了它们通往患者的路径，同时为股东创造可持续价值。</p>
<p>欲了解更多信息，请访问 www.puretechhealth.com 或在 LinkedIn 和 X（前身为 Twitter）上与我们联系 @puretechh。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含的声明可能是 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明，包括但不限于与我们在美国的退市和注销及相关时间、ADS 未来交易、未来前景、发展和战略相关的声明。前瞻性声明基于当前预期，并受到已知和未知的风险、不确定性及其他重要因素的影响，这些因素可能导致实际结果、表现和成就与当前预期有重大差异，包括但不限于在我们向 SEC 提交的 2025 年 12 月 31 日结束的 20-F 表格年度报告及其他监管文件中描述的 “风险因素” 下的风险、不确定性及其他重要因素。这些前瞻性声明基于关于公司当前和未来商业战略及其未来运营环境的假设。每个前瞻性声明仅在本新闻稿发布之日有效。除法律和监管要求外，我们不承担更新或修订这些前瞻性声明的任何义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260428539061/en/</p>
<p><strong>PureTech</strong></p>
<p>公共关系</p>
<p>publicrelations@puretechhealth.com</p>
<p>投资者关系</p>
<p>IR@puretechhealth.com</p>
<p><strong>英国/欧盟媒体</strong></p>
<p>Ben Atwell, Rob Winder</p>
<p>+44 (0) 20 3727 1000</p>
<p>puretech@fticonsulting.com</p>
<p><strong>美国媒体</strong></p>
<p>Justin Chen</p>
<p>jchen@tenbridgecommunications.com</p>
<p>来源：PureTech Health plc</p>

PRTC

PRTCY

<p>PureTech Health plc 宣布其计划自愿将其美国存托股票（ADSs）从纳斯达克退市，专注于在伦敦证券交易所（LSE）进行交易。此决定旨在提高运营效率，并与公司在英国的主要投资者基础保持一致。退市预计将在 2026 年 5 月 20 日左右生效，届时将向美国证券交易委员会（SEC）提交 Form 25。PureTech 的首席执行官强调，此举将简化治理结构并保护资本，使公司能够专注于推进其生物治疗产品组合</p>

<p><em>PureTech to maintain its primary listing on the London Stock Exchange</em></p>
<div class="lb-trans"><p><em>PureTech 将继续在伦敦证券交易所保持其主要上市</em></p>
</div><p><em>Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company’s portfolio</em></p>
<div class="lb-trans"><p><em>预计简化上市结构将提升运营效率，并将资源集中于推进公司的投资组合</em></p>
</div><p>BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (&#34;PureTech&#34; or the &#34;Company&#34;), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has notified The Nasdaq Stock Market LLC (“Nasdaq”) of its intention to voluntarily delist its American Depositary Shares (“ADSs”), each representing the right to receive ten (10) ordinary shares of the Company. Following the effectiveness of the delisting, PureTech’s ordinary shares will remain listed on the London Stock Exchange (“LSE”), which will continue to serve as the Company’s primary trading venue.</p>
<div class="lb-trans"><p>波士顿 --（商业资讯）--PureTech Health plc（纳斯达克：PRTC，伦敦证券交易所：PRTC）（&#34;PureTech&#34;或&#34;公司&#34;），一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司，今天宣布已通知纳斯达克证券市场有限责任公司（“纳斯达克”）其自愿退市美国存托股票（“ADSs”）的意图，每个 ADS 代表有权接收公司十（10）股普通股。在退市生效后，PureTech 的普通股将继续在伦敦证券交易所（“LSE”）上市，该交易所将继续作为公司的主要交易场所。</p>
</div><p>Following a review of the Company’s listing structure and shareholder trading patterns, the Board of Directors determined that maintaining a dual listing is no longer necessary. The substantial majority of trading volume, liquidity, and price discovery for PureTech’s shares occurs on the LSE, and the majority of the Company’s current investor base as well as the Company’s governance framework are centered in the United Kingdom.</p>
<div class="lb-trans"><p>经过对公司上市结构和股东交易模式的审查，董事会决定维持双重上市已不再必要。PureTech 股票的绝大多数交易量、流动性和价格发现发生在伦敦证券交易所，而公司当前投资者基础的主要部分以及公司的治理框架均集中在英国。</p>
</div><p>This decision reflects PureTech’s ongoing commitment to disciplined capital allocation, focused execution, and long-term shareholder value creation. The cost and regulatory and administrative demands of maintaining a dual listing are significant, and concentrating trading on the London Stock Exchange will simplify governance, streamline overhead, and align the Company’s structure with its operational and strategic priorities.</p>
<div class="lb-trans"><p>这一决定反映了 PureTech 对严格资本配置、专注执行和长期股东价值创造的持续承诺。维持双重上市的成本以及监管和行政要求是相当大的，集中交易于伦敦证券交易所将简化治理、精简开支，并使公司的结构与其运营和战略优先事项保持一致。</p>
</div><p>Following the delisting, and until such time as PureTech may consider terminating its American Depositary Receipt (“ADR”) program, PureTech expects its ADSs to be quoted and traded on the over-the-counter market via a sponsored Level 1 ADR program. No action is required to be taken by ADS holders at this time.</p>
<div class="lb-trans"><p>在退市后，直到 PureTech 考虑终止其美国存托凭证（“ADR”）计划为止，PureTech 预计其 ADS 将在场外市场通过赞助的一级 ADR 计划进行报价和交易。此时，ADS 持有者无需采取任何行动。</p>
</div><p>Robert Lyne, Chief Executive Officer of PureTech, commented:</p>
<div class="lb-trans"><p>PureTech 首席执行官 Robert Lyne 评论道：</p>
</div><p>“We have determined that concentrating our listing on the London Stock Exchange is the most effective way to support our shareholders and execute our strategy. This decision reflects where the meaningful trading volume and liquidity in our shares has consistently occurred, whilst maintaining access to both the UK and global investment community. By simplifying our listing structure, we are streamlining overhead, preserving capital, and ensuring that our resources are focused on advancing our differentiated portfolio and delivering long-term value.”</p>
<div class="lb-trans"><p>“我们已确定，将我们的上市集中在伦敦证券交易所是支持我们的股东和执行我们战略的最有效方式。这个决定反映了我们股票的有意义交易量和流动性始终发生的地方，同时保持对英国和全球投资社区的访问。通过简化我们的上市结构，我们正在精简开支、保护资本，并确保我们的资源集中于推进我们差异化的投资组合并创造长期价值。”</p>
</div><p>PureTech expects to file a Form 25 with the U.S. Securities and Exchange Commission (“SEC”) relating to the delisting of its ADSs on or about May 11, 2026. The delisting is expected to become effective ten days thereafter, with the last day of trading of the Company’s ADSs on Nasdaq expected to be on or about May 20, 2026.</p>
<div class="lb-trans"><p>PureTech 预计将在 2026 年 5 月 11 日左右向美国证券交易委员会（“SEC”）提交一份 25 号表格，涉及其 ADS 的退市。退市预计将在十天后生效，PureTech 的 ADS 在纳斯达克的最后交易日预计在 2026 年 5 月 20 日左右。</p>
</div><p>Following the delisting, PureTech intends to file a Form 15F with the SEC to deregister its securities and terminate its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Upon such filing, the Company’s reporting obligations with the SEC will be suspended immediately. The termination of the Company’s registration and reporting obligations is expected to become effective no later than 90 days after such filing if there are no objections from the SEC.</p>
<div class="lb-trans"><p>在退市后，PureTech 打算向 SEC 提交一份 15F 表格，以注销其证券并终止其根据 1934 年证券交易法（“交易法”）的报告义务。提交该表格后，公司的报告义务将立即暂停。如果 SEC 没有异议，公司的注册和报告义务的终止预计将在提交后不超过 90 天内生效。</p>
</div><p><strong>About PureTech Health</strong></p>
<div class="lb-trans"><p><strong>关于 PureTech Health</strong></p>
</div><p>PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&amp;D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.</p>
<div class="lb-trans"><p>PureTech Health 是一家中心辐射式生物治疗公司，致力于将科学变为现实并将创新转化为价值。我们通过一种经过验证的、资本高效的研发模式来实现这一目标，专注于具有验证药理学和未开发潜力的机会，以满足重要的患者需求。这一战略已经产生了数十个治疗候选药物，其中三个已获得美国 FDA 批准。通过识别、塑造和降低这些高信念资产的风险，并通过外部资本支持的专门结构进行规模化，我们加速了它们通往患者的路径，同时为股东创造可持续价值。</p>
</div><p>For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.puretechhealth.com 或在 LinkedIn 和 X（前身为 Twitter）上与我们联系 @puretechh。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our delisting and deregistration in the U.S. and related timing, plans for future trading of ADSs, future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption &#34;Risk Factors&#34; in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含的声明可能是 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明，包括但不限于与我们在美国的退市和注销及相关时间、ADS 未来交易、未来前景、发展和战略相关的声明。前瞻性声明基于当前预期，并受到已知和未知的风险、不确定性及其他重要因素的影响，这些因素可能导致实际结果、表现和成就与当前预期有重大差异，包括但不限于在我们向 SEC 提交的 2025 年 12 月 31 日结束的 20-F 表格年度报告及其他监管文件中描述的 “风险因素” 下的风险、不确定性及其他重要因素。这些前瞻性声明基于关于公司当前和未来商业战略及其未来运营环境的假设。每个前瞻性声明仅在本新闻稿发布之日有效。除法律和监管要求外，我们不承担更新或修订这些前瞻性声明的任何义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260428539061r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260428539061/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260428539061/en/</p>
</div><p><strong>PureTech</strong></p>
<div class="lb-trans"><p><strong>PureTech</strong></p>
</div><p>Public Relations</p>
<div class="lb-trans"><p>公共关系</p>
</div><p>publicrelations@puretechhealth.com</p>
<div class="lb-trans"><p>publicrelations@puretechhealth.com</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>IR@puretechhealth.com</p>
<div class="lb-trans"><p>IR@puretechhealth.com</p>
</div><p><strong>UK/EU Media</strong></p>
<div class="lb-trans"><p><strong>英国/欧盟媒体</strong></p>
</div><p>Ben Atwell, Rob Winder</p>
<div class="lb-trans"><p>Ben Atwell, Rob Winder</p>
</div><p>+44 (0) 20 3727 1000</p>
<div class="lb-trans"><p>+44 (0) 20 3727 1000</p>
</div><p>puretech@fticonsulting.com</p>
<div class="lb-trans"><p>puretech@fticonsulting.com</p>
</div><p><strong>US Media</strong></p>
<div class="lb-trans"><p><strong>美国媒体</strong></p>
</div><p>Justin Chen</p>
<div class="lb-trans"><p>Justin Chen</p>
</div><p>jchen@tenbridgecommunications.com</p>
<div class="lb-trans"><p>jchen@tenbridgecommunications.com</p>
</div><p>Source: PureTech Health plc</p>
<div class="lb-trans"><p>来源：PureTech Health plc</p>
</div>

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange | PRTC Stock News

PureTech 宣布计划自愿从纳斯达克退市其美国存托股票，并将交易集中在伦敦证券交易所 | PRTC 股票新闻